SLC5A2 and diabetic kidney disease: Although several studies with animal models suggest that long-term administration of SGLT2 inhibitors, including dapagliflozin, preserves pancreatic β-cell function with improved glucose homeostasis [9], [13], [14], [15], the influences of SGLT2 inhibition on diabetic nephropathy and renal function have not been elucidated.